Optimization of Pharmacotherapy for Chronic Pancreatitis: Use of Abc/Ved Analysis in Marketing and Pharmacoeconomic Studies

Background. Chronic pancreatitis (CP) is a progressive inflammatory disease that leads to irreversible damage to the pancreas, causing exocrine and endocrine insufficiency. The optimization of CP pharmacotherapy is a critical issue due to the increasing prevalence of the disease and the need for cost-effective and evidence-based treatment strategies. The use of ABC/VED analysis provides an opportunity to classify and prioritize medications based on their clinical significance and economic feasibility. Objective. The study aimed to optimize the pharmacotherapy of chronic pancreatitis by applying ABC/VED analysis in the context of marketing and pharmacoeconomic research. Methods. The research included a comprehensive review of regulatory documents, clinical guidelines, and pharmacoeconomic evaluations. A multidisciplinary expert survey was conducted involving 50 healthcare professionals, including gastroenterologists, surgeons, endocrinologists, general practitioners, and pharmacists. ABC analysis was applied to classify medications based on their cost contribution, while VED analysis categorized drugs into vital (V), essential (E), and desirable (D) groups. The study also assessed the regulatory framework for CP pharmacotherapy at national and international levels. Results. The study identified inconsistencies between national and international regulatory documents regarding CP pharmacotherapy. Among 30 analyzed medications, five drugs (Imipenem + Cilastatin, Meropenem, Metronidazole, Cefotaxime, Ciprofloxacin) were included in all four regulatory documents. ABC analysis showed that 82.21% of total expenditures were allocated to category A drugs, 15.54% to category B, and 2.25% to category C. VED analysis revealed that 43% of drugs were classified as vital, while 57% were essential, with no drugs considered non-essential. A combined ABC/VED matrix indicated that category A/V drugs had the highest expenditure share (41.54%), highlighting their priority in CP treatment. Conclusions. The application of ABC/VED analysis in CP pharmacotherapy enables a structured and economically justified approach to medication selection. The study revealed regulatory discrepancies that may impact drug accessibility and treatment effectiveness. The findings provide evidence-based recommendations for optimizing CP pharmacotherapy, ensuring alignment with both international standards and national healthcare policies. Future research should focus on integrating pharmacoeconomic assessments into clinical decision-making and updating national treatment protocols accordingly.